



PUBLIC NOTICE

REGULATORY POSITION ON COMPLEMENTARY MEDICINES CONTAINING ZINC PICOLINATE AND SELENIUM

Gaborone: 20/01/2026

The Botswana Medicines Regulatory Authority (BoMRA) has noted the cautionary media statement issued by the South African Health Products Regulatory Authority (SAHPRA) regarding complementary medicines containing Zinc Picolinate and Selenium.

BoMRA wishes to inform the public and all stakeholders in the health sector that several products containing Zinc Picolinate and Selenium, are registered and available for use in Botswana. The products mentioned have undergone rigorous regulatory evaluation process in accordance with the Medicines and Related Substances Act of 2013.

It is important to note that Botswana has been regulating complementary medicines for quality, safety and efficacy since 2013, an objective SAHPRA is aiming to achieve through the recent statement. This process ensures that registered products meet established requirements and adhere to internationally recommended safety limits, across different age groups including children,

The Authority further confirms that there is currently no recall or withdrawal of registered complementary medicines containing zinc picolinate and/or selenium from the Botswana market. These products, therefore, remain legally available for use unless new safety information emerges that necessitates a different regulatory position.

BoMRA continues to actively monitor emerging safety information related to all products, including complementary medicines containing zinc picolinate and selenium, through its post-market surveillance and pharmacovigilance systems, working closely with regional and international regulatory counterparts to ensure alignment with best regulatory practices and a timely response to any potential public health risks.

Members of the public are encouraged to use medicines responsibly by carefully reading and following product labels and package inserts, adhering to recommended dosages and age restrictions, and seeking advice from qualified healthcare professionals where necessary. Any suspected adverse reactions or safety concerns should be reported promptly to BoMRA.

BoMRA remains committed to protecting public health through ensuring continued access to quality, safe, and regulated medicines in Botswana.

For further information related to this notice, please visit the BoMRA website www.bomra.co.bw and other social media pages or contact the Botswana Medicines Regulatory Authority Public Relations: pr@bomra.co.bw or Tel: 3731728 / 363 2500 mobile: 76 895896

Report ADR -Tel: +267 362 0924 / 3731769 | email: reportadr@bomra.co.bw

END.